Agustina Alvarez
Sanofi (Spain)(ES)
Publications by Year
Research Areas
Diabetes Treatment and Management, Diabetes Management and Research, Metabolism, Diabetes, and Cancer, Parkinson's Disease Mechanisms and Treatments, Pancreatic function and diabetes
Most-Cited Works
- → Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial(2021)54 cited
- → Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial(2021)27 cited
- → Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial(2022)18 cited
- → The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial(2024)13 cited
- → Efficacy and safety of iGlarLixi versus IDegAsp : Results of a systematic literature review and indirect treatment comparison(2021)10 cited
- → Behavior of hospitalized severe influenza cases according to the outcome variable in Catalonia, Spain, during the 2017–2018 season(2021)8 cited
- → Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli‐ SWITCH study(2025)4 cited
- → Real‐world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12‐month, prospective observational study(2024)3 cited
- → Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 ( BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial(2022)3 cited
- → 747-P: Improved Treatment Perceptions with IGlarLixi vs. Premix Insulin in Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) + Oral Antihyperglycemic Drugs (OADs): Patient-Reported Outcomes (PROs) of the SoliMix Trial(2021)3 cited